Business Context and Reporting Period
Alterity Therapeutics Limited, a development stage enterprise based in Melbourne, Australia, filed this Form 6-K for the month of September 2026. The report was signed by Chairman Julian Babarczy on September 8, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on regulatory compliance rather than financial performance data.
Material Changes
No material changes versus a prior comparable period are disclosed in this filing. The document serves primarily as a vehicle to incorporate a specific exhibit by reference into existing registration statements.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The primary purpose of this submission is to incorporate Exhibit 99.1, a "Cleansing Notice Under Section 708A," into the company's Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the contents of Exhibit 99.1 (Cleansing Notice Under Section 708A) referenced in this filing.
- Confirm the status of the Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
- Review the company's most recent Form 20-F for actual financial performance data, as this 6-K contains none.